GAGuzal Abdullaeva

Guzal Abdullaeva

*This is an algorithmically generated author record based on publicly available information.

Guzal Abdullaeva has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect-Allele Frequencies at Cardiometabolic Risk Loci in an Uzbek Cohort from Tashkent: A Central Asian Reference and Priorities for Polygenic Score Validation

    by Alisher A. Abdullaev, Darya V. Zakirova, Sergei A. Kosushkin, Fazliddin Z. Xonboev, Guzal J. Abdullaeva, Rano B. Alieva, Shahlo U. Turdikulova

    Background/Objectives: Central Asian populations are almost entirely absent from genomic reference resources, yet Uzbekistan has one of the fastest rates of growth in age-standardised type 2 diabetes (T2D) incidence. Allele frequencies at cardiometabolic risk loci are unknown, limiting the interpretation of polygenic risk scores (PRS) derived elsewhere. We aimed to characterise effect-allele frequencies in an Uzbek cohort from Tashkent and quantify divergence from 1000 Genomes panels to guide future PRS evaluation. Methods: We genotyped 171 adults from Tashkent (131 with T2D, 40 without) on a custom Agilent SureSelect panel of cardiometabolic candidate SNPs. After quality control, 1939 variants were analysed. Effect-allele frequencies were compared with 1000 Genomes Phase 3 superpopulations (EUR, SAS, EAS, AFR) using Hudson FST and Nei’s genetic distance with bootstrap 95% CIs (1000 replicates). Case–control association was assessed descriptively using both unadjusted and age- and sex-adjusted additive logistic regression, with the adjusted model as primary. Results: Reference frequencies were available for 1533 of 1939 variants (1363 at MAF ≥ 0.05). Frequencies clustered with South Asian (FST = 0.077, 95% CI 0.065–0.089) and European panels (FST = 0.086, 95% CI 0.072–0.099), which were indistinguishable (ΔFST = −0.010, 95% CI −0.022 to 0.003) and more divergent from East Asian and African panels. Divergence from the European and South Asian panels was unrelated to nominal association status (Mann–Whitney p = 0.99 and 0.57). In the primary age- and sex-adjusted analysis, no variant survived multiple-testing correction (minimum Bonferroni-adjusted and false-discovery-rate q = 0.28), consistent with the unadjusted sensitivity analysis. Conclusions: This study provides the first systematic allele-frequency reference for cardiometabolic risk loci in an Uzbek cohort from Tashkent. The profile is closest to South Asian and European panels and identifies PRS from these ancestries as priority candidates for future local validation in Central Asian settings. The case–control analysis was underpowered and is reported descriptively.

  • Open Access

    Влияние фиксированной комбинированной терапии телмисартаном/амлодипином на кардиометаболические риски у пациентов с артериальной гипертензией

    by М Атоева, Г Абдуллаева, Г Хамидуллаева, С Бекметова, Х Юсупова, В Мансурова

    Aim. To evaluate the antihypertensive efficacy, effects on cardiometabolic risk factors, regression of target organ damage, and safety of 6-month fixed-combination therapy with telmisartan/amlodipine in patients with arterial hypertension (AH).Materials and Methods. The study enrolled 52 patients aged 18–65 years (mean age 51.90±13.84 years) with grade I–II AH according to the ESH 2023 classification. All patients received a fixed combination of telmisartan/amlodipine Assessment was performed at baseline and after 6 months, including office blood pressure measurement, echocardiography, applanation tonometry, duplex scanning of the carotid arteries, and evaluation of glucose, lipids, uric acid, hepatic transaminases, creatinine with calculation of glomerular filtration rate (GFR), and microalbuminuria (MAU) in morning urine.Results. After 6 months of fixed-combination telmisartan/amlodipine therapy, systolic blood pressure (SBP) decreased by 19.54% and diastolic blood pressure (DBP) by 16.67% (p<0.001). Significant regression of left ventricular hypertrophy (LVH) was observed, as indicated by a 7.6% reduction in left ventricular mass index (LVMI) (p<0.001). Pulse wave velocity (PWV) decreased significantly from 9.95±2.13 m/s to 9.00±1.12 m/s (p=0.019). The lipid profile improved during therapy, with reductions in total cholesterol (p=0.009) and LDL cholesterol (p=0.018).Conclusion. Six-month fixed-combination therapy with telmisartan/amlodipine demonstrated high antihypertensive efficacy, pronounced cardio-, vaso-, and nephroprotective effects, as well as a favorable impact on the metabolic profile in patients with AH, establishing it as a combination of choice, particularly in the presence of cardiometabolic risk factors.

  • Open Access

    Antigipertenziv preparatlarning kognitiv funksiyalarga ta’siri

    by Munisa Atoeva, Guzal Abdullaeva, Xafiza Yusupova, Iroda Ibragimova

    According to the World Health Organization data, 1.13 billion people worldwide suffer from arterial hypertension, with only 21% under proper control. Dementia currently negatively affects the quality of life of 55 million people worldwide, with one new case recorded every 3.2 seconds. Analyzing the effects of antihypertensive medications on cognitive function and evaluating protective mechanisms against dementia development is currently considered one of the urgent issues. There is reliable evidence that the effects of antihypertensive medications on cognitive function are related not only to blood pressure reduction but also to independent neuroprotective mechanisms. Angiotensin receptor blockers reduce dementia risk by 12-26% compared to other antihypertensive medications. Calcium channel blockers demonstrate 17% greater neuroprotective effects compared to other drug classes. ARBs and calcium channel blockers possess the best neuroprotective properties and are considered preferable for cognitive function protection. These effects occur independently of blood pressure reduction mechanisms.

  • Open Access

    Sex differences in 5-year risk of major adverse cardiovascular events in patients with coronary artery disease and elevated lipoprotein(a) levels

    by R. B. Alieva, A. B. Shek, A. A. Abdullaev, H. G. Fozilov, Sh. U. Khoshimov, G. D. Abdullaeva, D. Zakirova, L. E. Kan, A. R. Kim, R. A. Kurbanova, et al.

    Aim. To evaluate 5-year major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) and high lipoprotein(a) (Lp(a)) levels in the Uzbek population.Material and methods. The study included 216 patients (96 men and 120 women) hospitalized with a diagnosis of "CAD. Progressive angina", in whom MACE (cardiovascular death, non-fatal myocardial infarction and stroke) was assessed during 5 years of follow-up. The 2-∆∆Сt value, correlating with the number of LPA KIV-2 repeats, was determined in genomic DNA using quantitative real-time polymerase chain reaction (qPCR).Results. In patients with CAD with elevated Lp(a) in the quartile 4 ≥48 mg/dL, the MACE risk was 2 times higher (relative risk 2,0; 95% confidence interval 1,04-3,87, PConclusion. The 2-∆∆Сt value in the lower quartile associated with a low number of LPA KIV-2 repeats more accurately reflects the MACE risk in women with CAD. Also, the relative risk in women was lower in the upper quartile of apoA compared to the lower one.


  • Open Access

    Polipill yurak qon-tomir kasalliklarini oldini olishda: samaradorlik va istiqbollari

    by Shaxlo Fayzullayeva, Gulnoza Xamidullayeva, Guzal Abdullayeva, Xafiza Yusupova

    Yurak-qon tomir kasalliklari (YuQTK) dunyo bo‘ylab kasallanish va o‘limning yetakchi sabablaridan biri hisoblanadi. Profilaktikaning samaradorligini oshirish maqsadida bir nechta dorivor moddalarni o‘z ichiga olgan polipill konsepsiyasi ilgari surilgan. Ushbu maqolada polipillning birlamchi va ikkilamchi profilaktikadagi o‘rni, uning afzalliklari va kamchiliklari tahlil qilinadi. Polipill birlamchi profilaktikada arterial gipertenziya, dislipidemiya va tromboz rivojlanishini oldini olish orqali YuQTK xavfini kamaytirishi mumkin. Ikkilamchi profilaktikada esa yurak xuruji va insult kabi holatlarning qayta yuzaga kelish ehtimolini pasaytirishga yordam beradi. Shuningdek, polipill dori qabul qilish tartibini yaxshilash va umumiy iqtisodiy xarajatlarni kamaytirish imkonini beradi.

  • Open Access

    Arterial gipertenziyasi bor bemorlarda bo‘lmachalar fibrillyatsiyasi bilan asoratlanish xavfida: PITX2 rs6817105 va KCNN3 rs13376333 polimorfizmlarining roli

    by Zaringiz Mashkurova, Guzal Abdullayeva, Darya Zakirova, Gulrux Rajabova, Gulnoza Xamidullayeva, Alisher Abdullayev, Bekzod Rozibayev

    Aim. To determine the association between polymorphisms of the PITX2 (rs6817105) and KCNN3 (rs13376333) genes and the development of atrial fibrillation (AF) in patients with arterial hypertension (AH) in the Uzbek population. Materials and methods. The study included 154 patients with AH. Among them, paroxysmal AF was initially diagnosed in 21 patients (13.64%), persistent AF in 44 patients (28.57%), and permanent AF in 89 patients (57.79%). At the beginning of the study, the mean age of patients with AH and AF was 64.1±10.35 years. The control group consisted of AH patients without AF (n=91), with a mean age of 56.03±12.18 years. Clinical and instrumental examinations, including ECG, echocardiography, and Holter monitoring, were performed. Molecular genetic analysis of isolated DNA was carried out using real-time PCR. The association of polymorphisms with AF was assessed using logistic regression analysis and various inheritance models. Statistical analysis was performed using Statistica 10.0 and SNPassoc (R) software. Results. The study revealed statistically significant associations between the risk of atrial fibrillation development and the PITX2 gene rs6817105 polymorphism as well as the KCNN3 gene rs13376333 polymorphism in Uzbek patients with arterial hypertension. The PITX2 rs6817105 polymorphism showed a strong association with atrial fibrillation: carriage of the minor C allele increased the risk of AF development 2.76-fold under the log-additive inheritance model (OR = 2.76; p = 3.27×10⁻⁷). The KCNN3 rs13376333 polymorphism also demonstrated a significant association with AF. The C allele was significantly more frequent in patients with rhythm disorders and increased the risk of AF development under the log-additive model (OR = 1.63; p = 0.020). Conclusion. For the first time, an association between the PITX2 gene rs6817105 polymorphism and the KCNN3 gene rs13376333 polymorphism with atrial fibrillation has been identified in AH patients of the Uzbek population. These findings confirm the importance of these genetic markers in the pathogenesis of atrial fibrillation complicated by arterial hypertension and emphasize the relevance of genetic testing in this group of patients.

  • Open Access

    Comparative Analysis of The Effectiveness of Antihypertensive Therapy Including Spironolactone and Eplerenone in Patients With Essential Hypertension and Atrial Fibrillation

    by G. Zh. Abdullaeva, G. M. Radzhabova, N. H. Sherbadalova, M. T. Pulatova, Z. T. Mashkurova, R. B. Alieva, M. N. Khatamova, N. N. Ibragimov

    Aim . To perform a comparative analysis of the efficacy of antihypertensive therapy (AHT) containing spironolactone or eplerenone in patients with essential arterial hypertension (AH) and atrial fibrillation (AF). Material and methods . The study included 99 male and female patients with essential AH complicated by permanent AF, who were receiving the outpatient treatment at the National Specialized Scientific and Practical Medical Center of Cardiology (Tashkent). The patients aged 61.3±9.5 years, the mean duration of AH was 12.9±8.3 years. All patients were divided into two groups: Group 1, patients who completed a 6-month combination AHT containing spironolactone (n=51); Group 2, patients who completed a 6-month combination AHT containing eplerenone (n=48). AF was diagnosed by electrocardiogram (ECG) and/or 24-hour ECG monitoring according to standard diagnostic criteria. The ECG study was performed in compliance with the American Society of Echocardiography Guidelines in M- and B-modes. The degree of structural vascular alterations was determined by the intima-media thickness of the common carotid artery by duplex scanning and microalbuminuria in morning urine. The concentrations of sex hormones were measured by the enzyme immunoassay. The serum concentrations of lipids, glucose, creatinine, and uric acid were measured by the enzymatic method. The glomerular filtration rate (GFR) was calculated with the EPI formula. Results of all studies were considered statistically significant at p0.05) and from 54.8±8.8% at baseline to 58.2±6.4% in Group 2 (p0.05) and in Group 2, from 41.2±15.3 ml/m 2 at baseline to 37.3±13.5 ml/m 2 after the treatment (pvs. -0.36% in the spironolactone group. In men of Group 1, estradiol significantly increased from 13.9±12.6 pmol/l at baseline to 22.7±12.4 pmol/l (pConclusion . The good antihypertensive efficacy of the 6-month combination therapy containing eplerenone was significantly superior to spironolactone in achieving the target BP values. The eplerenone-containing treatment significantly improved LVEF and decreased LAVI compared to the spironolactone-containing treatment. A trend towards a beneficial effect of the AHT containing eplerenone on concentrations of sex hormones was noted in both women and men.

  • Open Access

    Orol dengizi mintaqasidagi arterial gipertenziyaning molekulyar-genetik xususiyatlari

    by Xurshid Ataniyazov, Xurshid Fozilov Фозилов, Gulnoz Xamidullayeva, G Abdullaeva

    Maqsad. Arterial gipertenziya (AG) – bu murakkab, ko‘p omilli kasallik bo‘lib, yurak-qon tomir kasalliklariga katta hissa qo‘shadi. Ayniqsa, Orol dengizi mintaqasida bu kasallik juda keng tarqalgan bo‘lib, unda genetik va ekologik omillar muhim rol o‘ynaydi. Ushbu tadqiqot Orol dengizi mintaqasidagi AG kasalligining molekulyar-genetik xususiyatlarini o‘rganishga qaratilgan. Materiallar va usullar. Tadqiqot Qoraqalpog‘iston Respublikasining Ellikkala tuman tibbiyot birlashmasining oilaviy poliklinikasida AG tashxisi qo‘yilgan 40-70 yoshdagi 1020 nafar bemorda o‘tkazildi. Genetik tahlil 407 nafar AG bemorida amalga oshirilib, gipertenziya bilan bog‘liq bo‘lgan asosiy genlarda polimorfizm mavjudligi aniqlangan. Natijalar. AG bemorlarida uchta muhim genetik polimorfizm aniqlangan: AGTR2 genidagi G1675A polimorfizmi, ADD1 genidagi G460T polimorfizmi va AGT genidagi C704T polimorfizmi. Ushbu polimorfizmlar Orol dengizi mintaqasi aholisi orasida AG rivojlanishi bilan bog‘liq ekanligi aniqlandi. Xulosa. Bu Orol dengizi mintaqasida AG bo‘yicha o‘tkazilgan birinchi keng miqyosli molekulyar- genetik tadqiqot bo‘lib, unda AGning yuqori tarqalishiga hissa qo‘shadigan genetik markerlar aniqlangan. Ushbu natijalar mintaqa aholisiga xos yurak-qon tomir kasalliklari uchun genetik xavf hisoblagichini ishlab chiqishda yordam beradi.

  • Open Access

    Orol dengizi mintaqasidagi arterial gipertenziyaning molekulyar-genetik xususiyatlari

    by Xurshid Ataniyazov, Xurshid Fozilov Фозилов, Gulnoz Xamidullayeva, G Abdullaeva

    Background. Arterial hypertension (AH) is a complex, multifactorial disease that significantly contributes to cardiovascular diseases. It is particularly prevalent in the Aral Sea region, where both genetic and environmental factors play a crucial role. This study focuses on the molecular-genetic characteristics of AH in the population of this region. Materials and methods. The study was conducted on 1020 patients aged 40-70 years, diagnosed with AH at the Ellikkala District Medical Association in the Republic of Karakalpakstan. Genetic analysis was performed on 407 AH patients to identify polymorphisms in key genes associated with hypertension. Results. Three significant genetic polymorphisms were identified in the AH patients: the G1675A polymorphism in the AGTR2 gene, the G460T polymorphism in the ADD1 gene, and the C704T polymorphism in the AGT gene. These polymorphisms were found to be associated with AH development in the Aral Sea region population. Conclusion. This is the first large-scale molecular-genetic study of AH in the Aral Sea region, revealing genetic markers that contribute to the high prevalence of AH in this area. These findings will help in the development of a genetic risk calculator for cardiovascular diseases specific to the region.

  • Open Access

    Сравнительная клиническая эффективность антикоагулянтной терапии апиксабаном генерического и оригинального происхождения у пациентов с артериальной гипертензией и постоянной фибрилляцией предсердий

    by Г Хамидуллаева, Г Абдуллаева, С Тургунбоев, Ж Сафаров, И Ибрагимова, Guliruh Раджабова

    Цель. Целью данного исследования было сравнение переносимости, безопасности и клиниче- ской эффективности апиксабана генерического и оригинального происхождения у пациентов с артериальной гипертензией (АГ) и постоянной неклапанной фибрилляцией предсердий (ФП). Материалы и методы. В это проспективное исследование было включено 50 пациентов с артериальной гипертензией 1-3 степени и постоянной неклапанной фибрилляцией предсердий. Пациенты были разделены на две группы: группа 1 (n=25) получала генерический апиксабан, группа 2 (n=25) — оригинальный апиксабан. В обеих группах назначалась доза апиксабана 10 мг в день, в сочетании с стандартной антигипертензивной терапией. Клинические и лабораторные исследования проводились до и после 1 месяца лечения, включая измерения артериального давления, эхокардиографию, биохимические анализы крови и коагулограмму. Результаты. В обеих группах было отмечено значительное снижение систолического и диасто- лического артериального давления. Изменений в эхокардиографических параметрах не было. Биохимические анализы показали снижение уровня креатинина и мочевой кислоты, а также увеличение протромбинового отношения, что указывает на положительную антикоагулянтную эффективность. Заключение. Генерический и оригинальный апиксабан продемонстрировали схожую безопас- ность и клиническую эффективность у пациентов с артериальной гипертензией и постоянной фибрилляцией предсердий, показав значительное снижение артериального давления и положи- тельный антикоагулянтный эффект.